Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...

Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES,.

Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, yesterday reviewed recent market research based on in-depth interviews (n=44)1 and quantitative surveys (n=1,504)2 of patients and physicians, showing the unmet need amongst lactose intolerance (LI) sufferers and interest in new treatment options from both patients’ and physicians’ perspectives. The call was hosted by Andrew J. Ritter, Ritter Pharmaceuticals’ CEO, and Daniel P. Lundberg, Founder and former Chief Marketing Officer at Vivelix Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals.

Definitive merger agreement with Qualigen, Inc. announced in January 2020 LOS ANGELES, March 31, 2020 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter.

LOS ANGELES, May 01, 2020 -- Form S-4 Declared Effective by the SEC and Ritter/Qualigen Merger Voting is Underway Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter.

The big shareholder groups in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) have power over the company. Large companies...

LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, announced that it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be explored or evaluated by the Company as part of this process include an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions involving the Company.

As previously announced, Ritter’s stockholders voted to approve the proposals required to complete the merger transaction, including a reverse stock split within a range of 1-for-25 to 1-for-35, as determined by Ritter’s board of directors. In connection with these approvals, the board of directors of Ritter has approved a reverse stock split of Ritter’s outstanding common stock at a ratio of one new share for every 25 shares outstanding, which is expected to become effective immediately prior to the consummation of the merger. Immediately following the closing, Ritter will be renamed “Qualigen Therapeutics, Inc.,” and is expected to trade on The Nasdaq Capital Market on a post-reverse stock split basis under the new ticker symbol “QLGN” beginning on Tuesday, May 26, 2020.

LOS ANGELES, Sept. 12, 2019 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that.

LOS ANGELES, May 06, 2020 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that Institutional Shareholder Services.

If you're interested in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR), then you might want to consider its beta (a...

LOS ANGELES, Nov. 13, 2019 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut.

Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal (GI) diseases, today announced the appointment of Anthony J. Lembo, M.D., to its Medical Advisory Board. “We are fortunate to have Dr. Lembo, who will be an invaluable resource, join our Medical Advisory Board,” said Andrew J. Ritter, CEO of Ritter Pharmaceuticals.

The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split. “We are urging all of our stockholders to take a few minutes to vote by phone, internet or mail on this important transaction,” said Ritter CEO Andrew J. Ritter.

As previously reported, Ritter Pharmaceuticals is holding a special meeting of stockholders this week on May 14, 2020, at which stockholders will be asked to approve various proposals related to the Company’s proposed merger with Qualigen, Inc. It is important to note that the merger cannot be consummated without the approval of each of the proposals, including a reverse stock split. While Ritter Pharmaceuticals is now in compliance with the stockholders’ equity requirement for continued listing, the combined company will need to conduct the reverse stock split in order to meet Nasdaq’s initial listing minimum bid price requirement of $4.00 per share.

The special meeting was adjourned to allow the Company additional time to solicit proxies in favor of the proposals to be acted on by stockholders at the meeting. As previously reported, the special meeting is being held to approve various proposals related to the Company’s proposed merger with Qualigen, Inc. These proposals are described in more detail in the joint proxy and consent solicitation statement/prospectus of Ritter dated April 9, 2020, furnished to Ritter’s stockholders in connection with the solicitation of proxies by the Ritter’s board of directors for use at the special meeting, and the supplement to the joint proxy and consent solicitation statement/prospectus, which was filed earlier today to provide certain clarifications, additions and updates.

LOS ANGELES, May 19, 2020 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the final vote.

LOS ANGELES, Aug. 14, 2019 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that.

Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals”, Ritter” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the U.S. Securities and Exchange Commission (the “SEC”) has declared effective its Registration Statement on Form S-4 relating to its previously announced proposed merger with Qualigen, Inc. (“Qualigen”) pursuant to the Agreement and Plan of Merger, dated as of January 15, 2020, as amended, by and among Ritter, RPG28 Merger Sub, Inc., and Qualigen. The special meeting of Ritter stockholders to vote on certain matters related to the proposed merger will be held virtually on May 14, 2020, at 9:00 a.m., Pacific Time.